Effects of quetiapine and haloperidol on body mass index and glycaemic control: A long-term, randomized, controlled trial

International Journal of Neuropsychopharmacology

Volumn 8, Issue 2, 2005, Pages 175-182

  Emsley, Robin ^a,b   Turner, H Jadri ^a   Schronen, Juan ^a   Botha, Karien ^a   Smit, Retha ^a   Oosthuizen, Piet P ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Clinical trial; Glucose metabolism; Haloperidol; Quetiapine; Weight gain

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HALOPERIDOL; HEMOGLOBIN A1C; QUETIAPINE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LONG TERM CARE; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; GLYCEMIC INDEX; HALOPERIDOL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044383637     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005067     Document Type: Article

References (39)

1. Allison DB, Casey DE (2001). Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62 (Suppl. 7), 22-31.
2. Allison DB, Mackell JA, McDonnell DD (2003). The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 54, 565-567.
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156, 1686-1696.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
5. APA (1994). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
6. Baptista T, Kin NM, Beaulieu S, de Baptista EA (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35, 205-219.
7. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, Hernandez L (2001a). Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34, 223-231.
8. Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernandez L (2001b). Antipsychotic drugs and obesity: is prolactin involved? Canadian Journal of Psychiatry 46, 829-834.
9. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Portilla MP, Fernandez I, Hernandez G (2003). Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research 62, 77-88.
10. Caligiuri M, Jeste DV (2004). Association of diabetes with dyskinesia in older psychosis patients. Psychopharmacology (Berlin) 176, 281-286.
11. Chouinard G, Ross-Chouinard A, Annable L, Jones B (1980). Extrapyramidal Symptom Rating scale [Abstract]. Canadian Journal of Neurological Science 7, 233.
12. Darvesh AS, Gudelsky GA (2003). Activation of 5-HT2 receptors induces glycogenolysis in the rat brain. European Journal of Pharmacology 464, 135-140.
13. Davidson MB, Schriger DL, Peters AL, Lorber B (1999). Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. Journal of the American Medical Association 281, 1203-1210.
14. Dhatt GS, Pum JK, Viljoen A, Jenner W (2003). Evaluation of HbA1C results in an external quality assessment scheme in South Africa. Clinica Chimica Acta 331, 147-151.
15. Emsley R, Turner J, Schronen J, Botha K, Smit R, Oosthuizen P (In Press). A single-blind, randomised trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry.
16. International Conference on Harmonization (1996). ICH Harmonised Tripartite Guidelines for Good Clinical Practice. Brookwood Medical Publications Ltd, Surrey, UK.
17. Joy CB, Adams CE, Lawrie SM (2001). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. CD003082.
18. Kay SR, Fizbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-267.
19. Koponen H, Saari K, Savolainen M, Isohanni M (2002). Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review. European Archives of Psychiatry and Clinical Neuroscience 252, 294-298.
20. Lean ME, Pajonk FG (2003). Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26, 1597-1605.
21. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry 160, 290-296.
22. Lindenmayer JP, Nathan AM, Smith RC (2001). Hyperglycemia associated with the use of atypical antipsychotics. Journal of Clinical Psychiatry 62 (Suppl. 23), 30-38.
23. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K (2003). Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. Journal of Child and Adolescent Psychopharmacology 13, 75-82.
24. McIntyre RS, McCann SM, Kennedy SH (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Canadian Journal of Psychiatry 46, 273-281.
25. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, Eggleston A (2003). Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Canadian Journal of Psychiatry 48, 689-694.
26. Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology Bulletin 25, 390-392.
27. Meltzer HY, Perry E, Jayathilake K (2002). Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research 59, 19-27.
28. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 59, 337-345.
29. Pollack S, Bruce P, Borenstein M, Lieberman J (1994). The resampling method of statistical analysis. Psychopharmacological Bulletin 30, 227-234.
30. Resnick HE, Valsania P, Halter JB, Lin X (1998). Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care 21, 1828-1835.
31. Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE (2000). Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 23, 187-191.
32. Ryan MC, Collins P, Thakore JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry 160, 284-289.
33. Ryan MC, Thakore JH (2002). Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences 71, 239-257.
34. Tardieu S, Micallef J, Gentile S, Blin O (2003). Weight gain profiles of new anti-psychotics: public health consequences. Obesity Reviews 4, 129-138.
35. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003). Insulin sensitivity and hyperprolactinemia. Journal of Endocrinological Investigation 26, 341-346.
36. Umhau JC, Petrulis SG, Diaz R, Rawlings R, George DT (2003). Blood glucose is correlated with cerebrospinal fluid neurotransmitter metabolites. Neuroendocrinology 78, 339-343.
37. Weiden PJ, Mackell JA, McDonnell DD (2004). Obesity as a risk factor for noncompliance. Schizophrenia Research 66, 51-57.
38. WHO (1980). World Health Organization Expert Committee on Diabetes Mellitus: Second Report. Technical Report 646. Geneva, Switzerland: World Health Organization.
39. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. British Journal of Psychiatry 184, 58-62.